Well that's wonderful. Cipro and levaquin have always been my go-to drugs. Larry Willis Retired and proud of it
Begin forwarded message: > Resent-From: [email protected] > From: greg <[email protected]> > Date: February 9, 2017 at 10:58:35 PM EST > To: <[email protected]> > Subject: [QUAD-L] Cipro Warning > > Just got a UTI. I always used Cipro, but they have a new danger warning. So > importent, its called a "Black Box" waning........ > > > > FDA Says Risks May Outweigh Benefits for Antibiotics Levaquin, Cipro > Posted May 16th, 2016 by Michelle Llamas & filed under FDA News & Recalls. > > Did you experience aortic complications after taking fluoroquinolones? > > On May 12, 2016, the U.S. Food and Drug Administration announced it is > requiring a stronger black box warning for common, popular antibiotics called > fluoroquinolones that include Levaquin (levofloxacin), Cipro (ciprofloxacin) > and Avelox (moxifloxacin) — medications taken by more than 26 million > Americans each year. > > “The U.S. Food and Drug Administration is advising that the serious side > effects associated with fluoroquinolone antibacterial drugs generally > outweigh the benefits for patients with sinusitis, bronchitis, and > uncomplicated urinary tract infections who have other treatment options,” the > FDA said in a Drug Safety Communication. “For patients with these conditions, > fluoroquinolones should be reserved for those who do not have alternative > treatment options.” > > The agency’s action comes after its FDA Advisory Committee meeting in > November 2015. This is not the first warning for these drugs released by the > FDA. It previously added boxed warnings in 2008 for tendon rupture and > tendinitis and again in 2013 for permanent nerve damage called peripheral > neuropathy. > > The new boxed warning advises patients and doctors that these antibiotics may > cause potentially permanent damage to muscles, tendons, joints, nerves and > the central nervous system. In patients with minor infections such as > sinusitis and bronchitis, the risk outweighs the benefits, the FDA panel > found. In these cases, other treatments are often available and the agency > strongly discourages doctors from prescribing them. > >
